Diselenide‐Based Dual‐Responsive Prodrug as Pyroptosis Inducer Potentiates Cancer Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Healthcare Materials"
DOI: 10.1002/adhm.202202135
Abstract: Pyroptosis is demonstrated to trigger antitumor immunity and represents a promising new strategy to potentiate cancer immunotherapy. The number of potent pyroptosis inducers, however, is limited and without tumor‐targeting capability, which inevitably causes damage in… read more here.
Keywords: dual responsive; pyroptosis; dse poc; cancer immunotherapy ... See more keywords